Arcutis Announces Appointment of Keith Leonard to Board of Directors
September 02 2021 - 4:10PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations to address the urgent needs of patients living with
immune-mediated dermatological diseases and conditions, or
immuno-dermatology, today announced that Keith R. Leonard Jr. has
been appointed to the Arcutis Board of Directors effective
September 2, 2021, replacing Ricky Sun, Ph.D., who has decided to
step down from the Board for personal reasons.
“We thank Ricky for his leadership over the past three years,”
commented Patrick Heron, Chairman of the Arcutis Board of
Directors. “He made significant contributions to Arcutis as the
company grew from a start-up to a company with a robust pipeline of
novel immuno-dermatology drug candidates on the cusp of its first
NDA submission. We wish him all the best in his future
endeavors.”
“We are delighted to welcome Keith to the Arcutis Board,” said
Frank Watanabe, Arcutis’ President and Chief Executive Officer.
“Keith adds to the depth of our board with over 25 years of
commercial, operational, and international leadership experience.
As a sitting chair of a publicly listed biotechnology company, a
former CEO of two public biotech companies, and someone who has
launched products at both large and emerging biopharmaceutical
companies, Keith’s insights will be instrumental as we prepare for
our first potential commercial launch of topical roflumilast.”
“I am thrilled to join the Arcutis board at this pivotal time,”
said Keith Leonard. “I am impressed with Arcutis’ product
candidates and the team’s dedication to providing important and
effective solutions for dermatology patients that do not require a
tradeoff between safety, efficacy, and tolerability. I look forward
to working with the Arcutis management team on its development and
commercialization efforts, and to bringing value to patients,
physicians, and shareholders.”
Keith Leonard is Chairman of the Board of UNITY Biotechnology,
where he served as Chief Executive Officer from 2016 to 2020, and
currently serves on the board of robotic surgery pioneer Intuitive
Surgical and Spanish biotech SANIFIT S.A.. Previously, Keith served
as the Chief Executive Officer of KYTHERA Biopharmaceuticals from
its founding in 2005 to its acquisition by Allergan plc in 2015.
Before KYTHERA, Keith spent 13 years at Amgen, ultimately as Senior
Vice President and General Manager at Amgen Europe, where he ran
all commercial operations in 28 countries. Prior to that position,
Keith ran Amgen’s manufacturing operations in Europe, established
Amgen’s presence in inflammation, served as Head of Information
Management, and had leadership roles in sales and marketing,
engineering, operations, and finance. Keith has been an Independent
Director of Anacor Pharmaceuticals, Affymax, and ARYx Therapeutics,
and was a venture partner with ARCH Venture Partners. He holds a
Master of Business Administration from The Anderson School of
Management, University of California, Los Angeles, a Master of
Science in Mechanical Engineering from University of California,
Berkeley, a Bachelor of Arts in History from University of
Maryland, College Park, and a Bachelor of Science in Engineering
from University of California, Los Angeles.About
ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a
medical dermatology company that champions meaningful innovation to
address the urgent needs of patients living with immune-mediated
dermatological diseases and conditions. With a commitment to
solving the most persistent patient challenges in dermatology,
Arcutis harnesses our unique dermatology development platform
coupled with our dermatology expertise to build differentiated
therapies against biologically validated targets. Arcutis’
dermatology development platform includes a robust pipeline with
seven clinical programs for a range of inflammatory dermatological
conditions, with our first NDA submission anticipated by the end of
2021 and three more Phase 3 clinical data readouts anticipated over
the next 18 months. The company’s lead product candidate, topical
roflumilast, has the potential to advance the standard of care for
plaque psoriasis, atopic dermatitis, scalp psoriasis, and
seborrheic dermatitis. For more information,
visit www.arcutis.com or follow Arcutis
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for roflumilast to revolutionize
the standard of care in plaque psoriasis and other inflammatory
dermatological conditions. These statements involve substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance, or
achievements to be materially different from the information
expressed or implied by these forward-looking statements and you
should not place undue reliance on our forward-looking statements.
Risks and uncertainties that may cause our actual results to differ
include risks inherent in the clinical development process and
regulatory approval process, the timing of regulatory filings, and
our ability to defend our intellectual property. For a further
description of the risks and uncertainties applicable to our
business, see the "Risk Factors" section of our Form 10-K filed
with U.S. Securities and Exchange Commission (SEC) on February 16,
2021, as well as any subsequent filings with the SEC. We undertake
no obligation to revise or update information herein to reflect
events or circumstances in the future, even if new information
becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
(805) 418-5006
asheldon@arcutis.com
Investors
Eric McIntyre, Head of Investor Relations
(805) 418-5006
emcintyre@arcutis.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e14992f0-879a-4428-9247-9ffd730d2ade
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2023 to Apr 2024